Which has preferable valuation & earnings, HYPD or TRAX?

First Tracks Biotherapeutics has lower revenue, but higher earnings than Hyperion DeFi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperion DeFi $810K 54.65 -$45.31M -$9.95 N/A First Tracks Biotherapeutics N/A N/A N/A N/A N/A

Is HYPD or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% First Tracks Biotherapeutics N/A N/A N/A

Which has stronger valuation and earnings, TRAX or LIAN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A N/A N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is TRAX or LIAN more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A LianBio N/A -33.17% -30.19%

Do analysts rate PHXM or TRAX?

First Tracks Biotherapeutics has a consensus price target of $38.25, indicating a potential upside of 113.93%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 First Tracks Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has preferable valuation & earnings, PHXM or TRAX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A First Tracks Biotherapeutics N/A N/A N/A N/A N/A

Is PHXM or TRAX more profitable?

Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A First Tracks Biotherapeutics N/A N/A N/A

Which has stronger earnings and valuation, TRAX or ADIL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A N/A N/A Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A

Is TRAX or ADIL more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Adial Pharmaceuticals N/A -162.82% -127.58%

Which has better valuation and earnings, TRAX or NMTR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A N/A N/A 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A

Is TRAX or NMTR more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A 9 Meters Biopharma N/A -584.97% -159.45%

First Tracks Biotherapeutics (TRAX) Competitors

$17.88 +0.24 (+1.36%)

Closing price 06/15/2026 04:00 PM Eastern

Extended Trading

$17.32 -0.56 (-3.10%)

As of 06/15/2026 05:43 PM Eastern

Compare

TRAX vs. HYPD, LIAN, PHXM, ADIL, and NMTR

Should you buy First Tracks Biotherapeutics stock or one of its competitors? MarketBeat compares First Tracks Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with First Tracks Biotherapeutics include Hyperion DeFi (HYPD), LianBio (LIAN), PHAXIAM Therapeutics (PHXM), Adial Pharmaceuticals (ADIL), and 9 Meters Biopharma (NMTR). These companies are all part of the "biotechnology" industry.

How does First Tracks Biotherapeutics compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Hyperion DeFi currently has a consensus target price of $5.65, indicating a potential upside of 93.49%. First Tracks Biotherapeutics has a consensus target price of $38.25, indicating a potential upside of 113.93%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

25.8% of Hyperion DeFi shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Hyperion DeFi and Hyperion DeFi both had 2 articles in the media. First Tracks Biotherapeutics' average media sentiment score of 1.44 beat Hyperion DeFi's score of 0.48 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperion DeFi	Neutral
First Tracks Biotherapeutics	Positive

First Tracks Biotherapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
First Tracks Biotherapeutics	N/A	N/A	N/A

First Tracks Biotherapeutics has lower revenue, but higher earnings than Hyperion DeFi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	54.65	-$45.31M	-$9.95	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Summary

First Tracks Biotherapeutics beats Hyperion DeFi on 6 of the 9 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to LianBio?

First Tracks Biotherapeutics (NASDAQ:TRAX) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

First Tracks Biotherapeutics' return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
LianBio	N/A	-33.17%	-30.19%

74.8% of LianBio shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for First Tracks Biotherapeutics and 0 mentions for LianBio. First Tracks Biotherapeutics' average media sentiment score of 1.44 beat LianBio's score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
First Tracks Biotherapeutics	Positive
LianBio	Neutral

First Tracks Biotherapeutics currently has a consensus price target of $38.25, suggesting a potential upside of 113.93%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe First Tracks Biotherapeutics is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

First Tracks Biotherapeutics beats LianBio on 8 of the 10 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to PHAXIAM Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for First Tracks Biotherapeutics and 0 mentions for PHAXIAM Therapeutics. First Tracks Biotherapeutics' average media sentiment score of 1.44 beat PHAXIAM Therapeutics' score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
First Tracks Biotherapeutics	Positive

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A

First Tracks Biotherapeutics has a consensus price target of $38.25, indicating a potential upside of 113.93%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

First Tracks Biotherapeutics beats PHAXIAM Therapeutics on 6 of the 8 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Adial Pharmaceuticals?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

In the previous week, Adial Pharmaceuticals had 5 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 7 mentions for Adial Pharmaceuticals and 2 mentions for First Tracks Biotherapeutics. First Tracks Biotherapeutics' average media sentiment score of 1.44 beat Adial Pharmaceuticals' score of 0.45 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
First Tracks Biotherapeutics	Positive
Adial Pharmaceuticals	Neutral

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

First Tracks Biotherapeutics presently has a consensus target price of $38.25, indicating a potential upside of 113.93%. Adial Pharmaceuticals has a consensus target price of $17.17, indicating a potential upside of 502.34%. Given Adial Pharmaceuticals' higher possible upside, analysts plainly believe Adial Pharmaceuticals is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

First Tracks Biotherapeutics' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Summary

First Tracks Biotherapeutics beats Adial Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to 9 Meters Biopharma?

First Tracks Biotherapeutics (NASDAQ:TRAX) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for First Tracks Biotherapeutics and 0 mentions for 9 Meters Biopharma. First Tracks Biotherapeutics' average media sentiment score of 1.44 beat 9 Meters Biopharma's score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
First Tracks Biotherapeutics	Positive
9 Meters Biopharma	Neutral

22.3% of 9 Meters Biopharma shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

First Tracks Biotherapeutics' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
9 Meters Biopharma	N/A	-584.97%	-159.45%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

First Tracks Biotherapeutics currently has a consensus target price of $38.25, indicating a potential upside of 113.93%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than 9 Meters Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

First Tracks Biotherapeutics beats 9 Meters Biopharma on 8 of the 10 factors compared between the two stocks.

Get First Tracks Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAX vs. The Competition

Export

Metric	First Tracks Biotherapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$623.87M	$453.94M	$6.74B	$12.07B
Dividend Yield	N/A	3.88%	2.67%	5.66%
P/E Ratio	N/A	3.17	23.90	24.57
Price / Sales	N/A	6,463.61	511.88	141.49
Price / Cash	N/A	13.13	27.48	37.92
Price / Book	N/A	86.81	10.47	6.78
Net Income	N/A	-$96.07M	$3.56B	$337.32M
7 Day Performance	11.96%	1.23%	0.66%	2.20%
1 Month Performance	5.80%	0.23%	1.90%	4.06%
1 Year Performance	N/A	53.32%	24.86%	29.91%

First Tracks Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAX First Tracks Biotherapeutics	N/A	$17.88 +1.4%	$38.25 +113.9%	N/A	$623.87M	N/A	N/A	N/A	Positive News Gap Up
HYPD Hyperion DeFi	4.0076 of 5 stars	$2.87 -2.1%	$5.65 +96.9%	+19.7%	$43.62M	$810K	N/A	40	Gap Up
LIAN LianBio	N/A	$0.16 +15.0%	N/A	-57.9%	$17.28M	N/A	N/A	110	Gap Up
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
ADIL Adial Pharmaceuticals	3.5778 of 5 stars	$2.18 -1.6%	$22.75 +946.0%	-67.4%	$4.65M	N/A	N/A	20	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAX) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. HYPD, LIAN, PHXM, ADIL, and NMTR

How does First Tracks Biotherapeutics compare to Hyperion DeFi?

Summary

How does First Tracks Biotherapeutics compare to LianBio?

Summary

How does First Tracks Biotherapeutics compare to PHAXIAM Therapeutics?

Summary

How does First Tracks Biotherapeutics compare to Adial Pharmaceuticals?

Summary

How does First Tracks Biotherapeutics compare to 9 Meters Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. HYPD, LIAN, PHXM, ADIL, and NMTR

How does First Tracks Biotherapeutics compare to Hyperion DeFi?

Do analysts prefer HYPD or TRAX?

Do institutionals and insiders hold more shares of HYPD or TRAX?

Does the media favor HYPD or TRAX?

Is HYPD or TRAX more profitable?

Which has preferable valuation & earnings, HYPD or TRAX?

Summary

How does First Tracks Biotherapeutics compare to LianBio?

Is TRAX or LIAN more profitable?

Do insiders & institutionals believe in TRAX or LIAN?

Which has stronger valuation and earnings, TRAX or LIAN?

Does the media favor TRAX or LIAN?

Do analysts rate TRAX or LIAN?

Summary

How does First Tracks Biotherapeutics compare to PHAXIAM Therapeutics?

Do institutionals and insiders believe in PHXM or TRAX?

Which has preferable valuation & earnings, PHXM or TRAX?

Does the media favor PHXM or TRAX?

Is PHXM or TRAX more profitable?

Do analysts rate PHXM or TRAX?

Summary

How does First Tracks Biotherapeutics compare to Adial Pharmaceuticals?

Which has stronger earnings and valuation, TRAX or ADIL?

Does the media favor TRAX or ADIL?

Do institutionals & insiders believe in TRAX or ADIL?

Do analysts rate TRAX or ADIL?

Is TRAX or ADIL more profitable?

Summary

How does First Tracks Biotherapeutics compare to 9 Meters Biopharma?

Does the media prefer TRAX or NMTR?

Do insiders & institutionals believe in TRAX or NMTR?

Is TRAX or NMTR more profitable?

Which has better valuation and earnings, TRAX or NMTR?

Do analysts rate TRAX or NMTR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools